Sun Pharma gets USFDA nod for generic cardiac drug
New Delhi: Sun Pharmaceutical Industries said its subsidiary has received approval from the US health regulator to market generic version of GSK's Coreg CR, extended release capsules in the American market.
One of the company's wholly-owned subsidiaries has received final approval from US Food and Drug Administration (USFDA) for the generic product in strengths of 10mg, 20mg, 40mg and 80 mg, Sun Pharma said in a statement.
Coreg CR extended release capsules are indicated for treating various heart conditions, including heart failure and high blood pressure.
As per IMS, Coreg CR had annual sales of around USD 208 million in the US for the 12 months ended August 2017.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd